HC Wainwright Has Positive Outlook of RenovoRx Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for RenovoRx to a loss of $0.03 from a prior loss estimate of $0.08. The firm projects improving earnings, reaching positive EPS by 2028.
• RenovoRx’s latest quarterly results surpassed expectations, with a $0.05-per-share loss versus the estimated $0.07 loss and revenue of $0.91 million compared with the $0.70 million forecast.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $8.50, while RNXT recently traded at $1.20.

RenovoRx, Inc. (NASDAQ:RNXT - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings estimates for shares of RenovoRx in a research note issued to investors on Friday, August 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.03) per share for the quarter, up from their previous estimate of ($0.08). The consensus estimate for RenovoRx's current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for RenovoRx's Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.04) EPS, FY2028 earnings at $0.08 EPS, FY2029 earnings at $0.18 EPS and FY2030 earnings at $0.26 EPS.

A number of other research analysts have also recently weighed in on the stock. Weiss Ratings raised shares of RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, July 17th. Wall Street Zen raised shares of RenovoRx from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Ascendiant Capital Markets increased their price target on RenovoRx from $13.50 to $14.00 and gave the company a "buy" rating in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $8.50.

RenovoRx Price Performance

Shares of RNXT stock opened at $1.20 on Tuesday. RenovoRx has a 1-year low of $0.70 and a 1-year high of $1.50. The firm's 50-day simple moving average is $0.96 and its 200-day simple moving average is $0.94. The firm has a market cap of $54.06 million, a P/E ratio of -3.87 and a beta of 0.99.

RenovoRx (NASDAQ:RNXT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The business had revenue of $0.91 million for the quarter, compared to analysts' expectations of $0.70 million. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 138.07%.

Hedge Funds Weigh In On RenovoRx

A number of hedge funds have recently bought and sold shares of RNXT. AIGH Capital Management LLC lifted its holdings in RenovoRx by 30.8% in the first quarter. AIGH Capital Management LLC now owns 3,706,197 shares of the company's stock worth $3,682,000 after acquiring an additional 872,303 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in RenovoRx during the 2nd quarter worth $98,000. Bleichroeder LP increased its position in RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company's stock worth $504,000 after buying an additional 61,379 shares during the period. Citadel Advisors LLC acquired a new stake in RenovoRx in the third quarter worth $154,000. Finally, Geode Capital Management LLC lifted its stake in RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company's stock valued at $467,000 after buying an additional 31,730 shares during the last quarter. 3.10% of the stock is currently owned by institutional investors and hedge funds.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company's lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source